齐拉西酮治疗精神分裂症Meta分析  

Meta-analysis of comparative study on ziprasidone in the treatment of schizophrenia

作　　者：汪正华[1] 阳中明[1] 

机构地区：[1]安徽芜湖市第四人民医院,241002

出　　处：《临床精神医学杂志》2010年第4期252-253,共2页Journal of Clinical Psychiatry

摘　　要：目的:探讨齐拉西酮治疗精神分裂症的疗效及其与对照药的差异。方法:应用Meta分析对9项研究齐拉西酮与利培酮治疗精神分裂症对照研究的文献进行再分析,评价其合并效应量的大小和综合显著性检验。结果:齐拉西酮治疗前后的自身对照,合并效应量(d=3.50,95%CI为3.23,3.77),综合显著性检验(χ2=25.52,P<0.01),显示齐拉西酮治疗精神分裂症前后症状学变化有非常显著性差异,效应极强。齐拉西酮与利培酮在治疗2周和治疗结束时组间比较,显示齐拉西酮与利培酮疗效没有显著性差异。结论:齐拉西酮治疗精神分裂症与利培酮疗效相当。Objective： To study the efficacy of ziprasidone in the treatment of schizophrenia. Method： A total of 9 comparative studies of ziprasidone and risperidone in the treatment of schizophrenia were analyzed by meta-analysis in therapeutic effects and side effects. Results： The significant difference in symptoms between before and after treatment by ziprasidone was found （d =3. 50,95% CI 3. 23,3. 77; χ2 =25. 52,P 0. 01） . Comparison between ziprasidone and risperidone at week 2 and the end after treatment showed that there was no significant difference with respect to the clinical efficacy. Conclusion： The therapeutic effects of ziprasidone and risperidone for treating schizophrenia were similar.

关 键 词：精神分裂症 齐拉西酮 利培酮 META分析 

分 类 号：R749.3[医药卫生—神经病学与精神病学]